Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

A novel drug combination, improvements in quality of life, and breakthrough hemolysis control are among the clinical highlights in paroxysmal nocturnal hemoglobinuria (PNH) presented at the 2024 ...

Victor Bultó, president of Novartis in the US, said that the approval of Fabhalta “may mean that patients can reset their expectations of living with PNH.” Analysts at Jefferies have ...